

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>			
				Application Number		To Be Assigned	
				Filing Date		Concurrently Herewith	
				First Named Inventor		Thomas P. Kennedy	
				Group Art Unit			
				Examiner Name			
Sheet	1	of	2	Attorney Docket Number		046428/275157	
<b>U. S. PATENT DOCUMENTS</b>							
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear	
JDA	1	US-4,148,885		Renoux et al.	04-10-79		
	2	US-4,426,372		Borch	01-17-84		
	3	US-4,581,224		Borch	04-08-86		
	4	US-4,594,238		Borch	06-10-86		
	5	US-4,645,661		Schonbaum	02-24-87		
	6	US-4,762,705		Rubin	08-09-88		
	7	US-4,999,347		Sorenson	03-1991		
	8	US-5,035,878		Borch et al.	07-30-91		
	9	US-5,187,193		Borch et al.	02-16-93		
	10	US-5,380,747		Medford et al.	01-10-95		
	11	US-5,679,777		Anderson et al.	10-21-97		
	12	US-5,750,351		Medford et al.	05-12-98		
	13	US-5,759,517		Anderson et al.	06-02-98		
	14	US-5,773,209		Medford et al.	06-03-98		
	15	US-5,773,231		Medford et al.	06-30-98		
	16	US-5,783,596		Medford et al.	07-21-98		
	17	US-5,786,344		Ratain et al.	07-28-98		
	18	US-5,792,787		Medford et al.	08-11-98		
↓	19	US-6,156,794		Faiman et al.	12-05-2000		
JDA	20	US-6,548,540		Kennedy	04-2003		

<sup>1</sup> Unique citation designation number.

<sup>2</sup> See attached Kinds of U.S. Patent Documents.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>			
				Application Number		To Be Assigned	
				Filing Date		Concurrently Herewith	
				First Named Inventor		Thomas P. Kennedy	
				Group Art Unit			
				Examiner Name			
Sheet	2	of	2	Attorney Docket Number		046428/275157	
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials	Cite No.	Foreign Patent Document Office <sup>3</sup> Number <sup>4</sup> Kind Code (if known) <sup>5</sup>		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
JDA	21	PCT	WO 99/34763		Yeda Research and Development Co. Ltd.	07-15-99	
JDA	22	PCT	WO 99/34784		Yeda Research and Development Co. Ltd.	07-15-99	
JDA	23	GB	2 081 094	A	Regents of the University of Minnesota	02-17-82	
JDA	24	JP	4202139	A		07-22-92	A
<b>NON PATENT LITERATURE DOCUMENTS</b>							
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
JDA	25	<i>Protective Effects of Glutathione on Diethyldithiocarbamate (DDC) Cytotoxicity: A Possible Mechanism</i> , L. D. Trombetta et al., Toxicology and Applied Pharmacology 93, pp. 154-164, 1988					
JDA	26	<i>Disulfiram and Tumor Inhibition</i> , H. K. A. Schirmer et al., Transactions of American Association of Genito-Urinary Surgeons, Vol. 58, pp. 63-66, 1966					
JDA	27	<i>Inhibition of Meth-A Tumor Cell Proliferation in Combined Use of Disulfiram with Catalase</i> , H. Mashiba et al., Toxicology Letters, 61, pp. 75-80, 1992					
JDA	28	<i>Phase I Study of the Combination of Disulfiram with Cisplatin</i> , D. J. Stewart et al., Am. J. Clin. Oncol. (CCT), Vol. 10, No. 6, pp. 517-519, 1987					
	29	<del><i>Antitumor Activity of New Nitrosoureas on Yoshida Sarcoma Ascites Cells In Vivo</i>, M. Habs et al., Institute of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg, FRG, pp. 438-444,</del>					
JDA	30	<i>A Review of the Modulation of Cisplatin Toxicities by Chemoprotectants</i> , R. T. Dorr, Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, pp. 131-154, 1996					
JDA	31	<i>Cytotoxic Interactions of Zn<sup>2+</sup> In Vitro: Melanoma Cells Are More Susceptible Than Melanocytes</i> , J. Borovansky et al., Melanoma Research, Vol. 7, pp. 449-453, 1997					
Examiner Signature	/James Anderson/				Date Considered	07/26/2006	


\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO (Revised 07/2005)								<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number		10/787,030			
				Filing Date		February 25, 2004			
				First Named Inventor		Thomas P. Kennedy			
				Group Art Unit		1614			
				Examiner Name					
Sheet	1	of	1	Attorney Docket Number		045936/275157			
<b>FOREIGN PATENT DOCUMENTS</b>									
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached		
JDA	32	WO 97/05867 A		02/20/1997	British Technology Group		YES		
JDA	33	WO 01/17522 A		03/15/2001	Charlotte-Mecklenburg Hospital Authority		YES		
<b>OTHER DOCUMENTS</b>									
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					English Language Translation Attached		
JDA	34	NOBEL C.S. et al., <i>Mechanism of dithiocarbamate inhibition of apoptosis: thiol oxidation by dithiocarbamate disulfides directly inhibits processing of the caspase-3 proenzyme</i> , <u>Chemical Research in Toxicology</u> , June 1997, Vol. 10, No. 6, pp. 636-643.					YES		
JDA	35	MESHNICK S.R. et al., <i>Antimalarial activity of diethyldithiocarbamate. Potentiation by Copper</i> , <u>Biochemical Pharmacology</u> , July 15, 1990, Vol. 40, No. 2, pp. 213-216.					YES		
JDA	36	<i>HIV infection. Dithiocarb treatment in AIDS is unsuccessful</i> , <u>Fortschritte der Medizin</u> , November 20, 1991, Vol. 109, No. 33, p. 18.					YES		
JDA	37	DANIEL, K.G., et al., <i>Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells</i> , <u>Breast Cancer Research</u> , Vol. 7, 2005, pp. R897-R908.					YES		
Examiner Signature	/James Anderson/				Date Considered	07/26/2006			

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.